This case report documents a reactivation of a pulmonary pathology,
beginning some hours after the administration of a first dose of
BNT162b2 mRNA vaccine, in a patient having presented a symptomatic
pulmonary form of covid-19 one month before. The lessons to be learned
and the possible involved mechanisms are discussed.